Study on the Sakigake designation system and the enlightenment to ChinaCHEN Miao-feng, XIE Jin-ping1281-1284
The selection of comparators for health technology assessment:international experience and enlightenmentAI Dan-dan, SUI Bin-yan, DUAN Cheng-a-xin, XU Qian, ZHAO Kun1285-1292
Reconstruct the antitrust analysis model of pharmaceutical patent reverse payment settlement agreements:focusing on the first case of anti-monopoly reviewWANG Xin-chen, GE Zhang-zhi1293-1301
The research progress of lazertinib:a third-generation epidermal growth factor receptor tyrosine kinase inhibitorHUANG Lu, LUO Meng-yu, WANG Zhi-feng, HONG Yi1302-1308
Introduction and interpretation of U.S.FDA Inspection of Injectable Products for Visible Particulates Guidance for Industry(draft guidance)LI Yue, DONG Wu-jun, ZHANG Yao, WANG Ya-min1309-1314
Comparison of the dissolution profiles of quetiapine fumarate tablets from different manufacturers in five dissolution mediasWANG Lu-nan, MA Ling-yun, ZHAI Chen-fei, LIU Qian, HUANG Yin, FENG Yu-fei, XU Ming-di1315-1324
Chemical constituents,pharmacological effects and clinical applications of Corydalis saxicola Bunting and predictive analysis on quality markerZENG Yong-zhu, ZHONG Hua-shuai, SU Xiao-dan, LU Jian-mei, MAI Wan-ting, HUANG Qiu-jie, YE Yong1325-1335
Advances in N-acetylgalactosamine and its derivatives as delivery vehicles of small interfering RNA and antisense oligonucleotidesLI Da-wei, MAO Kai-fan, YANG Xue-hua, XUE Song, LIU Zheng-ping1336-1344
Research progress in the co-development of next-generation sequencing companion diagnosis and antitumor drugsSONG Peng, TIAN Li-juan1345-1350
Research progress of the mechanism,metabolism and distribution of vigabatrinZHENG Qiang, FAN Min, GE Jin-fang1351-1357